Close Menu

NEW YORK (Precision Oncology News) – French biotech Transgene's investigational new drug application for an individualized viral vector-based immunotherapy for ovarian cancer has been accepted by the US Food and Drug Administration, allowing the firm to move forward with Phase I studies.

TG4050 is the lead candidate utilizing Transgene's Myvac viral vector-based immunotherapy platform and is designed to recognize and destroy tumors using a patient's own cancer-specific genetic mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.